Silence Therapeutics reports durable efficacy data for divesiran in polycythemia vera

Silence Therapeutics presented Phase 1 follow-up data showing divesiran reduced phlebotomy requirements from 80 procedures to 5 during treatment, with benefits persisting post-dose. Phase 2 results are expected in August 2026, potentially supporting a best-in-class profile for this first-in-class siRNA therapy.